Publication:
Analysis of 50 neurodegenerative genes in clinically diagnosed early-onset Alzheimer’s disease

dc.contributor.authorVo Van Giauen_US
dc.contributor.authorVorapun Senanarongen_US
dc.contributor.authorEva Bagyinszkyen_US
dc.contributor.authorSeong Soo A. Anen_US
dc.contributor.authorSangyun Kimen_US
dc.contributor.otherSeoul National University Bundang Hospitalen_US
dc.contributor.otherGachon Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2020-01-27T07:47:54Z
dc.date.available2020-01-27T07:47:54Z
dc.date.issued2019-03-02en_US
dc.description.abstract© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and prion diseases have a certain degree of clinical, pathological, and molecular overlapping. Previous studies revealed that many causative mutations in AD, PD, and FTD/ALS genes could be found in clinical familial and sporadic AD. To further elucidate the missing heritability in early-onset Alzheimer’s disease (EOAD), we genetically characterized a Thai EOAD cohort by Next-Generation Sequencing (NGS) with a high depth of coverage, capturing variants in 50 previously recognized AD and other related disorders’ genes. A novel mutation, APP p.V604M, and the known causative variant, PSEN1 p.E184G, were found in two of the familiar cases. Remarkably, among 61 missense variants were additionally discovered from 21 genes out of 50 genes, six potential mutations including MAPT P513A, LRRK2 p.R1628P, TREM2 p.L211P, and CSF1R (p.P54Q and pL536V) may be considered to be probably/possibly pathogenic and risk factors for other dementia leading to neuronal degeneration. All allele frequencies of the identified missense mutations were compared to 622 control individuals. Our study provides initial evidence that AD and other neurodegenerative diseases may represent shades of the same disease spectrum, and consideration should be given to offer exactly embracing genetic testing to patients diagnosed with EOAD. Our results need to be further confirmed with a larger cohort from this area.en_US
dc.identifier.citationInternational Journal of Molecular Sciences. Vol.20, No.6 (2019)en_US
dc.identifier.doi10.3390/ijms20061514en_US
dc.identifier.issn14220067en_US
dc.identifier.issn16616596en_US
dc.identifier.other2-s2.0-85063957213en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/50233
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063957213&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemical Engineeringen_US
dc.subjectChemistryen_US
dc.subjectComputer Scienceen_US
dc.titleAnalysis of 50 neurodegenerative genes in clinically diagnosed early-onset Alzheimer’s diseaseen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063957213&origin=inwarden_US

Files

Collections